Buy or sell Synthace stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Synthace Stock

Synthace is a Life Sciences R&D cloud platform that enables experiments to be automated, with the resultant data seamlessly integrated.

About Synthace Stock

Synthace is a Life Sciences R&D cloud platform that enables experiments to be rapidly automated, with the resultant data seamlessly integrated. Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Funding History

August 2013$1.4M
December 2014$3.0M
August 2017$10.1M
May 2018$3.1M
December 2018$25.4M
November 2021$6.7M
December 2021$26.5M

Management

CSO & Co-founder

Markus Gershater

Head of Bioinformatics

Michael Sadowski

Director, Marketing & Strategic Partnerships

Sybil Wong

Chairman of Board of Directors

Bob Wiederhold

Board Member

Sean Ward

CEO

Guy Levy-Yurista

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Synthace or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 260K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo